Abstract
Between 2015 and 2019, a private health insurer in Colombia started using two new groups of oral antidiabetics: iDPP4 (sitagliptin, vildagliptin, saxagliptin, linagliptin) or iSGLT2 (dapagliflozin, canagliflozin and empagliflozin). The objective was to analyze clinical outcomes and costs of patients in the year before and after the new medication was introduced.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
